公司資料
AN2 Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ANTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.81 USD (+0.35%)
收盤價
最後更新: 2026年8月21日
147M USD
市值
股價為何變動
The latest monitored company update is “AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer.” The corresponding closing-price reaction is not yet available.
公司概覽
Boron-Based Drug Development
AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology.
Epetraborole in Polycythemia Vera
AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera. The program will evaluate whether the drug can maintain hematocrit control and reduce phlebotomy frequency.
Epetraborole in M. abscessus
Epetraborole is also being studied in an investigator-initiated Phase 2 trial for *Mycobacterium abscessus* lung disease. The study is intended to establish clinical proof of concept and inform a potential pivotal program.
Chagas Disease Program
AN2-502998 is an oral CPSF3 inhibitor for chronic Chagas disease. Its development is supported by translational efficacy work in naturally infected non-human primates.
Oncology Discovery Pipeline
AN2 has declared a boron-containing ENPP1 inhibitor for solid tumors and is also researching PI3Kα and other difficult-to-drug targets in oncology and bone disorders.
未來催化劑
- IND filing for the EBO-PV-201 study of epetraborole in polycythemia vera in the third quarter of 2026.
- Initiation of Phase 2 enrollment in EBO-PV-201 in the fourth quarter of 2026.
- Initiation of a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease in late 2026.
- Initial Part 1 data from EBO-PV-201 during 2027.
- Topline results from the investigator-initiated Phase 2 epetraborole study in *M. abscessus* lung disease in late 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。